Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort

Journal of the National Cancer Institute

Volumn 98, Issue 1, 2006, Pages 69-72

  Jacobs, Eric J ^a   Rodriguez, Carmen ^a   Brady, Kerri A ^a   Connell, Cari J ^a   Thun, Michael J ^a   Calle, Eugenia E ^a  

^a AMERICAN CANCER SOCIETY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; COLESTYRAMINE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NONSTEROID ANTIINFLAMMATORY AGENT; PRAVASTATIN; SIMVASTATIN;

ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; CASE CONTROL STUDY; CLINICAL TRIAL; COLORECTAL CANCER; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; DRUG USE; FOLLOW UP; HUMAN; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; QUESTIONNAIRE; RISK REDUCTION; UNITED STATES;

ADULT; AGED; ANTICARCINOGENIC AGENTS; ANTICHOLESTEREMIC AGENTS; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; QUESTIONNAIRES; UNITED STATES;

EID: 30344441524     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djj006     Document Type: Article

References (18)

1. Siegel D, Lopez J, Meier J. Use of cholesterol-lowering medications in the United States from 1991 to 1997. Am J Med 2000;108:496-9.
2. Narisawa T, Fukaura Y, Terada K, Umezawa A, Tanida N, Yazawa K, et al. Prevention of 1,2-dimethylhydrazine-induced colon tumorigenesis by HMG-CoA reductase inhibitors, pravastatin and simvastatin, in ICR mice. Carcinogenesis 1994;15:2045-8.
3. Narisawa T, Fukaura Y, Tanida N, Hasebe M, Ito M, Aizawa R. Chemopreventive efficacy of low dose of pravastatin, an HMG-CoA reductase inhibitor, on 1,2-dimethylhydrazine-induced colon carcinogenesis in ICR mice. Tohoku J Exp Med 1996;180:131-8.
4. Narisawa T, Morotomi M, Fukaura Y, Hasebe M, Ito M, Aizawa R. Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats. Jpn J Cancer Res 1996;87: 798-804.
5. Agarwal B, Rao CV, Bhendwal S, Ramey WR, Shirin H, Reddy BS, et al. Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effect of sulindac. Gastroenterology 1999;117:838-17.
6. Kim KP, Whitehead C, Piazza G, Wargovich MJ. Combinatorial chemoprevention: Efficacy of lovastatin and exisulind on the formation and progression of aberrant crypt foci. Anticancer Res 2004;24:1805-11.
7. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, et al. Statins and the risk of colorectal cancer. N Engl J Med 2005;352:2184-92.
8. Pedersen TR, Berg K, Cook TJ, Faergeman O, Haghfelt T, Kjekshus J, et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1996;156:2085-92.
9. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9.
10. Downs JR, Clearfield DO, Weis S, Whitney E, Shapiro D, Beere P, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998;279:1615-22.
11. Probstfield JL, Davis BR. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care. JAMA 2002;288:2998-3007.
12. Blais L, Desgagne A, LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: A nested case-control study. Arch Intern Med 2000; 160:2363-8.
13. Graaf MR, Beiderbeck AB, Egberts ACG, Richel DJ, Guchelaar H. The risk of cancer in users of statins. J Clin Oncol 2004;22: 2388-94.
14. Kaye JA, Jick H. Statin use and cancer risk in the General Practice Research Database. Br J Cancer 2004;90:635-7.
15. Friis S, Poulsen AH, Johnsen SP, McLaughlin JK, Fryzek JP, Dalton SO, et al. Cancer risk among statin users: A population-based cohort study. Int J Cancer 2005;114:643-7.
16. Calle EE, Rodriguez C, Jacobs EJ, Almon ML, Chao A, McCullough ML, et al. The American Cancer Society Cancer Prevention Study II Nutrition Cohort - rationale, study design and baseline characteristics. Cancer 2002;94:2490-501.
17. Calle EE, Terrell DD. Utility of the national death index for ascertainment of mortality among Cancer Prevention Study II participants. Am J Epidemiol 1993;137:235-41.
18. Cox DR. Regression models and life tables (with discussion). J R Stat Soc (B) 1972;34: 187-220.